TBD Therapeutics Inc. develops breakthrough solution for the treatment of NEUROPATHIC PAIN
Our Technology / IP
-
A novel proprietary camphor based synthetic small molecule that was designed & developed by Prof. Mechoulam, The Hebrew University, Jerusalem, Israel.
-
It activates a sequence of processes, via initial attachment to the CB2 receptors throughout the body’s Endo-Cannabinoid System. Resulting in, secretion of natural intrinsic pain & inflammation modulation compounds in the body that can prevent or reduce development of pain and inflammation.
-
It was proved to have anti-inflammatory and immuno-protective properties.
-
Demonstrated equipotent analgesic effect as morphine and ibuprofen in chemotherapy-induced neuropathic pain model in mice.
-
It is a safe, efficacious, non-psychoactive (not a narcotic) CB2 receptor agonist with high affinity to CB2 receptors, high potency and high level of penetration into injured tissues.
-
The Patent (HU-910) – “New chemical entity/composition of matter” , for the novel molecule, comprise of a wide range of relevant therapeutic indications, was registered and a patent was granted to Hebrew University, in key strategic markets including the USA, Europe and RoW (rest of world).